Opthea Limited IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Opthea Limited | OPT - NASDAQ |
$17.26-$17.26 | $13.50 | $11.05 | 9.5 million ADSs | 10/16/2020 |
| Citigroup, SVB Leerink | ||||||
Co-Manager(s): Truist Securities, Oppenheimer & Co | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-09-24 Terms Added 2020-10-09 | ||||||
Opthea Limited Quote & Chart - Click for current quote - OPT
IPO Boutique aggregates information on public companies and private companies, such as "OPT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Opthea Limited (adapted from Opthea Limited prospectus):
They are a clinical stage biopharmaceutical company developing a novel therapy for the treatment of highly prevalent and progressive retinal diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage biopharmaceutical company developing a novel therapy for the treatment of highly prevalent and progressive retinal diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "OPT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.